目的 建立人肝癌组织裸鼠移植瘤模型，对其特性进行鉴定，并应用于抗肿瘤药物制剂疗效的观察。方法 将人原发肝癌手术新鲜组织移植于BALB/c裸鼠皮下，建立人肝癌组织裸鼠移植瘤动物模型；于同体移植后第15 天连续ig给予长科制剂（CKBM），通过观察动物日常状况、接种部位出现肿块时间，测定瘤体体积和质量、抑瘤率以及进行组织病理学观察，初步评价CKBM的抗肿瘤疗效。结果 人肝癌组织裸鼠移植瘤保持了人肝癌组织特性，并能通过同体移植传代；观察发现CKBM对人肝癌荷瘤裸鼠的抑瘤率达45.71%，对癌细胞生长有一定的抑制作用。结论 在成功建立人肝癌组织裸鼠移植瘤模型基础上，观察发现CKBM具有一定的抗肿瘤疗效。

Objective The human hepatocellular carcinoma model was established by implantation in BALB/c nude mice. Its characteristics were certified in the model which was used for the observation of antitumor efficacy. Methods Human hepatocellular carcinoma were sc implanted to BALB/c nude mice for the establishment of the implantation model of the human hepatocellular carcinoma in BALB/c nude mice. The nude mice were exposed to the pharmaceuticals from CK Life Sciences Limited by ig on day 15 after the implantation to find out its healing efficacy through the animal reflecting, the occurring time, volume, weight of tumors, the rate of tumor inhibited, and pathological histology. Results The characteristics of human hepatocellular carcinoma could be kept with passaging by autograft. The tumor inhibiting rate of the pharmaceuticals was 45.71%, showing the certain inhibitory effect on growth of tumor cells. Conclusion A certain antitumor efficacy of the pharmaceuticals made by CK Life Sciences Limited is found out on the basis on the human hepatocellular carcinoma model in nude mice established successfully.